Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 2 diabetes
Biotech
AstraZeneca pays $185M to reenter obesity race, drops SCD drug
Months after dropping its own oral GLP-1 agonist, the Big Pharma has agreed to pay $185 million for a similar challenger to Lilly, Novo and Pfizer.
Nick Paul Taylor
Nov 9, 2023 5:00am
Novo Nordisk taps GE HealthCare for ultrasound diabetes therapy
Oct 19, 2023 10:54am
Better Therapeutics rolls out digital app for Type 2 diabetes
Oct 16, 2023 10:51am
Fractyl's GLP-1 obesity gene therapy outdoes semaglutide—in mice
Oct 4, 2023 4:24pm
EASD: Dexcom CGMs notch wins in Type 2 diabetes, pregnant users
Oct 4, 2023 9:24am
Abbott finds FreeStyle Libre, GLP-1 adherence rise together
Sep 29, 2023 10:24am
